XOMA Corporation
XOMA announced today the pricing of 9,500,000 shares of its common
stock at a price to the public of $5.25 per share. In addition, XOMA has
granted the underwriters a 30-day option to purchase up to an
additional 1,425,000 shares of common stock on the same terms and conditions.
The shares will be issued pursuant to a prospectus supplement filed as part of
a shelf registration statement previously filed with the Securities and
Exchange Commission (SEC) on Form S-3. XOMA anticipates its aggregate net
proceeds from the offering will be approximately $46.5 million after deducting
the underwriting discount and estimated offering expenses payable by XOMA.
XOMA intends to use the net proceeds from the offering for continued
development, preclinical testing and clinical studies related to gevokizumab
and the XMet platform, general research and development, business development
and other corporate purposes. The offering is expected to close on or about
December 18, 2013, subject to customary closing conditions.
Credit Suisse Securities (USA) LLC and Jefferies LLC are acting as joint book
running managers. Cowen and Company, LLC, Piper Jaffray & Co. and RBC Capital
Markets, LLC are acting as co-managers. Piper Jaffray & Co. is acting as a
financial advisor to XOMA in connection with the offering.
This press release does not constitute an offer to sell or a solicitation of
an offer to buy nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction. This press release is being issued pursuant to and in
accordance with Rule 134 under the Securities Act of 1933, as amended. Any
offer, if at all, will be made only by means of a prospectus supplement and
accompanying prospectus forming a part of the effective registration
statement. Copies of the prospectus supplement and accompanying prospectus
relating to the offering may be obtained from Credit Suisse Securities (USA)
LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010,
by telephone at 800-221-1037, or by email at
newyork.prospectus@credit-suisse.com, or from Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY
10022, by telephone at 877-547-6340, or by email at
prospectus_department@jefferies.com. XOMA intends to file a final prospectus
supplement relating to the offering with the SEC, which will be available
along with the accompanying prospectus filed with the SEC in connection with
the shelf registration, on the SEC's website at www.sec.gov.
About XOMA
XOMA discovers and develops innovative antibody therapeutics.
Forward-Looking Statements
The statements contained herein concerning XOMA's expectations regarding the
completion, size and terms of the proposed offering and the anticipated net
proceeds from the offering are forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements are based on assumptions that may not
prove accurate. Actual results could differ materially from those anticipated
due to certain risks, including the proposed offering is subject to the
satisfaction of customary closing conditions. There can be no assurance that
XOMA will be able to complete the offering on the anticipated terms, or at
all. Risks and uncertainties relating to XOMA and its business can be found in
the "Risk Factors" section of XOMA's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2013, and in the preliminary prospectus supplement
related to the proposed offering filed with the SEC on or about the date
hereof. Consider such risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's views only
as of the date of this press release and should not be relied upon as
representing its views as of any subsequent date. XOMA disclaims any
obligation to update any forward-looking statement, except as required by
applicable law.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in